Retrospective analysis: clinical outcomes in patients treated with EGFR TKIs in Taiwan
Patients treated with erlotinib had similar overall survival and PFS to those patients treated with gefitinib or afatinib, despite having the highest proportion of brain metastases at baseline.1
Baseline characteristics were unbalanced across the treatment groups
Overall survival did not differ among the treatment groups.
PFS did not differ among the treatment groups.